Allen Lee Cohn
Physician at Aberdeen Ave, Englewood, CO

License number
Colorado 27525
Issued Date
Jul 10, 1986
Renew Date
May 1, 2015
Expiration Date
Apr 30, 2017
Type
Physician
Address
Address
10460 E Aberdeen Ave, Englewood, CO 80111

Professional information

Allen Cohn Photo 1

Taxane Analogs For The Treatment Of Brain Cancer

US Patent:
8409574, Apr 2, 2013
Filed:
Aug 20, 2010
Appl. No.:
12/859990
Inventors:
James D. McChesney - Etta MS, US
Gilles Tapolsky - Boulder CO, US
David E. Emerson - Longmont CO, US
John Marshall - Washington DC, US
Tauseef Ahmed - Briarcliff Manor NY, US
Allen Cohn - Englewood CO, US
Michael Kurman - Upper Saddle River NJ, US
Manuel Modiano - Tucson AZ, US
International Classification:
A61K 39/00, A61K 31/415, A61K 31/335, A01N 43/52, A01N 43/32, C07D 309/00
US Classification:
4241331, 514393, 514452, 549358
Abstract:
Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.


Allen Cohn Photo 2

Taxane Analogs For The Treatment Of Brain Cancer

US Patent:
2013025, Sep 26, 2013
Filed:
Mar 5, 2013
Appl. No.:
13/785753
Inventors:
Gilles Tapolsky - Louisville KY, US
David E. Emerson - Longmont CO, US
John Marshall - Washington DC, US
Tauseef Ahmed - Briarcliff Manor NY, US
Allen Cohn - Englewood CO, US
Michael Kurman - Upper Saddle River NJ, US
Manuel Modiano - Tucson AZ, US
International Classification:
A61K 31/357
US Classification:
514452, 549358
Abstract:
Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.